Anzeige
Mehr »
Login
Freitag, 10.07.2020 Börsentäglich über 12.000 News von 632 internationalen Medien
Massive Expansion im Gold-District: Fliegt jetzt der Deckel weg?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 725180 ISIN: DE0007251803 Ticker-Symbol: SAZ 
Hamburg
10.07.20
14:21 Uhr
94,50 Euro
+0,50
+0,53 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
STADA ARZNEIMITTEL AG Chart 1 Jahr
5-Tage-Chart
STADA ARZNEIMITTEL AG 5-Tage-Chart
PR Newswire
350 Leser
Artikel bewerten:
(2)

Enzymatica and STADA Extend Agreement for Europe

STOCKHOLM, May 25, 2020 /PRNewswire/ -- Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The launch of ViruProtect in these new markets is expected to the fall of 2020.

Enzymatica and STADA have an agreement for sales and distribution of ViruProtect in Belgium and Austria since 2017. This agreement is now extended to another 19 countries in Europe. Most of these markets are countries in Eastern Europe but do also include a few Western European markets. The OTC Cough/Cold/Flu/Sore Throat market in these countries totals SEK 23.6 billion1) (ex factory sales). The estimated annual growth rate over the next five years is 2.4%. 1)

ViruProtect will be sold as a medical device in the countries covered by the extended agreement, and the first deliveries are expected to take place after the summer. The ordered volumes include both 7 ml and 20 ml bottles of ViruProtect.

"We are very pleased that STADA has great trust in our cold spray and has now extended our agreement to a large amount of markets in Europe. With a proven success of ColdZyme in a number of existing markets, there is a strong potential for further growth of our business in Europe," says Fredrik Lindberg, CEO of Enzymatica.

1.Nicholas Hall, 2018

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 10 am CET on May 25, 2020.

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily

conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

For more information, please contact:

Claus Egstrand
Chief Operating Officer Enzymatica AB
Phone: +44-7780-22-8385
E-mail: claus.egstrand@enzymatica.com

Carl-Johan Wachtmeister
Communication manager Enzymatica AB
Phone: +46(0)701-88-50-21
Email: carl-johan.wachtmeister@enzymatica.com

Enzymatica's certified adviser is Erik Penser Bank. Phone: +46(0)8-463-83-00. Email: certifiedadviser@penser.se

Enzymatica AB Ideon Science Park, SE-223 70 Lund, Sweden Telefon +46 46-286 31 00

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/enzymatica-and-stada-extend-agreement-for-europe,c3118882

The following files are available for download:

https://mb.cision.com/Main/18091/3118882/1252908.pdf

Release

STADA ARZNEIMITTEL-Aktie jetzt für 0€ handeln - auf Smartbroker.de
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.